Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

ICE/ced-3 cysteine protease inhibitors in development at Idun

Feb. 25, 1999

Connetics begins pivotal trial of relaxin for scleroderma therapy

Feb. 25, 1999

Experiments show skeletal muscle capable of bone formation when transplanted into animals

Feb. 25, 1999

Phase III enrollment for Colloral completed

Feb. 24, 1999

Autoimmune antibodies linked to blood clotting defect

Feb. 23, 1999

Calmodulin analogues with antiinflammatory activity available for licensing from OMRF

Feb. 23, 1999

Roche discloses inhibitors of TNF-alpha/TGF-alpha release, keratinocyte proliferation

Feb. 18, 1999

VUFB's phase III antirheumatic agent is available for licensing

Feb. 18, 1999

More from SmithKline Beecham on p38 MAP kinase inhibitors

Feb. 18, 1999

Antiarthritic effects, mechanism and GI safety of S-2474 evaluated in rat model

Feb. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...